Sparsentan News
Sparsentan currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Sparsentan with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g,...
- Evidence level: L5
- Predicted indications (20):
- alopecia (94.5%)
- congenital hypotrichosis milia (94.5%)
- hypotrichosis simplex of the scalp (94.3%)
- diffuse alopecia areata (94.2%)
- angioedema (93.0%)
- lichen disease (93.0%)
- dermatitis (91.8%)
- potassium deficiency disease (91.7%)
- pulmonary arteriovenous malformation (disease) (91.2%)
- fetal erythroblastosis (91.2%)
- open-angle glaucoma (91.1%)
- lichen planus pemphigoides (91.0%)
- pulmonary arterial hypertension (91.0%)
- hypertrophic lichen planus (90.9%)
- annular atrophic lichen planus (90.9%)
- lichen planus pigmentosus (90.9%)
- primary hereditary glaucoma (90.3%)
- amyopathic dermatomyositis (89.7%)
- acrodermatitis chronica atrophicans (89.7%)
- psoriasis (89.7%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.